Why is this medication prescribed?

Blenrep (belantamab mafodotin) is a medication prescribed for the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is specifically used for patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

How should this medicine be used?

Blenrep (belantamab mafodotin) is administered as an intravenous infusion by a healthcare professional. Here’s a general guideline on how it’s typically used:

• Dosage: The dosage of Blenrep is determined by the prescribing doctor based on factors such as the patient’s weight, overall health, and response to treatment.
• Schedule: Blenrep is usually administered once every three weeks (every 21 days), although the specific schedule may vary depending on the individual patient’s needs and response to treatment.
• Infusion: The medication is administered intravenously over a specified period of time, typically lasting about 30 minutes. The infusion is given in a healthcare setting such as a clinic or hospital by a trained healthcare professional.
• Monitoring: During and after the infusion, patients are closely monitored for any signs of adverse reactions or side effects. Vital signs may be checked regularly, and patients may be asked about any symptoms they experience.
• Precautions: Prior to starting treatment with Blenrep, patients may undergo various tests and evaluations to assess their overall health and suitability for the medication. Certain precautions may also be taken to minimize the risk of side effects or complications.
• Follow-Up: Patients receiving Blenrep will typically have regular follow-up appointments with their healthcare provider to monitor their response to treatment, assess for any side effects, and make any necessary adjustments to the treatment plan.

It’s important for patients to follow their healthcare provider’s instructions carefully and to attend all scheduled appointments for infusions and follow-up care. Additionally, any concerns or questions about Blenrep or its use should be discussed with the prescribing doctor or healthcare team.

Other uses for this medicine

Blenrep (belantamab mafodotin) is primarily used for the treatment of multiple myeloma in patients who have received prior therapies. However, it’s important to note that medications are sometimes prescribed off-label, meaning they’re used to treat conditions other than those approved by regulatory agencies. While Blenrep is primarily indicated for multiple myeloma, there may be ongoing research or clinical trials exploring its potential use in other types of cancer or conditions.

What special precautions should I follow?

As for special precautions to follow when using Blenrep, here are some important points to consider:

• Medical History: Before starting treatment with Blenrep, it’s crucial to inform your healthcare provider about your complete medical history, including any pre-existing conditions, allergies, or medications you are currently taking.
• Pregnancy and Breastfeeding: Blenrep can cause harm to a developing fetus, so it’s essential to use effective contraception during treatment and for at least 5 months after the last dose. It’s also not recommended for use during breastfeeding.
• Eye Disorders: Blenrep can cause severe vision problems, including changes in vision, blurred vision, and blindness. Regular eye exams are recommended during treatment, and patients should promptly report any vision changes to their healthcare provider.
• Liver and Kidney Function: Blenrep may affect liver and kidney function, so regular monitoring of liver and kidney function tests may be necessary during treatment.
• Infusion Reactions: Infusion reactions, including fever, chills, nausea, and vomiting, can occur during or after Blenrep administration. Patients are closely monitored during infusion, and appropriate supportive care may be provided as needed.
• Hematologic Toxicity: Blenrep can cause decreases in blood cell counts, including white blood cells, red blood cells, and platelets. Regular blood tests are performed to monitor for any abnormalities, and treatment may be adjusted accordingly.
• Fluid Retention: Blenrep may cause fluid retention, which can lead to swelling and weight gain. Patients should report any symptoms of fluid retention to their healthcare provider.
• Interstitial Lung Disease: Blenrep has been associated with interstitial lung disease, a potentially serious condition that affects the lungs. Patients should promptly report any new or worsening respiratory symptoms, such as cough, shortness of breath, or difficulty breathing.

These are just some of the precautions to consider when using Blenrep. It’s essential to discuss any questions or concerns with your healthcare provider before starting treatment.

What special dietary instructions should I follow?

Regarding special dietary instructions for Blenrep, there are no specific dietary restrictions associated with its use. However, it’s essential to maintain a healthy and balanced diet to support overall well-being during cancer treatment. If you have any dietary concerns or specific dietary restrictions, discuss them with your healthcare provider or a registered dietitian.

What should I do if I forget a dose?

If you forget a dose of Blenrep, contact your healthcare provider as soon as possible for guidance. It’s important not to double the dose to make up for a missed one. Your healthcare provider will advise you on the best course of action based on your specific situation and treatment plan.

What side effects can this medication cause?

Blenrep (belantamab mafodotin) can cause various side effects, some of which may be severe. It’s essential to be aware of these potential side effects and to promptly report any concerning symptoms to your healthcare provider. Common side effects of Blenrep include:

• Eye Disorders: Blurred vision, changes in vision, and other eye-related problems are common side effects of Blenrep. These may include dry eyes, eye irritation, and eye pain. Regular eye exams are recommended during treatment.
• Infusion Reactions: During or shortly after receiving Blenrep infusion, patients may experience infusion reactions such as fever, chills, nausea, vomiting, and headache. Healthcare providers typically monitor patients closely during the infusion process to manage these reactions.
• Decreased Blood Cell Counts: Blenrep can cause decreases in various blood cell counts, including white blood cells, red blood cells, and platelets. This may lead to increased risk of infections, anemia, and bleeding. Regular blood tests are performed to monitor blood cell counts during treatment.
• Fatigue: Feeling tired or fatigued is a common side effect of Blenrep treatment. It’s important to get plenty of rest and to avoid activities that may exacerbate fatigue.
• Nausea and Vomiting: Blenrep may cause nausea and vomiting, although these symptoms are usually mild to moderate in severity.
• Fluid Retention: Blenrep can lead to fluid retention, causing symptoms such as swelling in the legs, ankles, or feet, and sudden weight gain.
• Fever: Fever is a common side effect of Blenrep treatment, particularly during the infusion process.
• Skin Reactions: Skin reactions such as rash, itching, and dry skin may occur with Blenrep treatment.
• Liver and Kidney Problems: Blenrep may affect liver and kidney function, leading to abnormalities in liver and kidney function tests.
• Interstitial Lung Disease: In some cases, Blenrep has been associated with interstitial lung disease, a potentially serious condition that affects the lungs. Symptoms may include cough, shortness of breath, and difficulty breathing.

These are some of the common side effects associated with Blenrep treatment. It’s important to discuss any concerns or questions about side effects with your healthcare provider. Additionally, seek medical attention if you experience any severe or persistent side effects while taking Blenrep.

What should I know about storage and disposal of this medication?

Storage and Disposal:

• Storage: Blenrep vials should be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light until time of use. Do not freeze. If needed, during administration, the diluted solution may be stored at room temperature (up to 25°C or 77°F) for up to 4 hours. After dilution, discard any unused portion of the vial.
• Disposal: Any unused portion of Blenrep or materials used in the preparation and administration should be disposed of properly according to local regulations and guidelines for handling cytotoxic agents. It’s important to follow specific disposal instructions provided by your healthcare provider or pharmacist.

In case of emergency/overdose

In case of an emergency or overdose with Blenrep, seek immediate medical attention or contact a poison control center (1-800-222-1222 in the United States). There is no specific antidote for Blenrep overdose. Treatment is supportive and symptomatic, and it may involve monitoring and management of adverse reactions.

What other information should I know?

• Before starting Blenrep treatment, inform your healthcare provider about all medications you are taking, including prescription, over-the-counter, vitamins, and herbal supplements.
• Attend all scheduled appointments for Blenrep infusions and medical monitoring as recommended by your healthcare provider.
• Report any new or worsening symptoms, side effects, or concerns to your healthcare provider promptly.
• Follow all instructions provided by your healthcare provider for safe and effective use of Blenrep, including any special precautions or dietary instructions.
• Keep Blenrep and all medications out of the reach of children and pets.
• Do not share Blenrep with others, as it is prescribed specifically for you based on your medical condition and needs.

It’s important to have a clear understanding of storage, disposal, emergency procedures, and other relevant information when using Blenrep. If you have any questions or concerns, don’t hesitate to discuss them with your healthcare provider or pharmacist.